The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type
Open accessAbstract
The altered metabolism of tumors has been considered a target for anticancer therapy. However, the relationship between distinct tumor-initiating lesions and anomalies of tumor metabolism in vivo has not been addressed. We report that MYC-induced mouse liver tumors significantly increase both glucose and glutamine catabolism, whereas MET-induced liver tumors use glucose to produce glutamine. Increased glutamine catabolism in MYC-induced liver tumors is associated with decreased levels of glutamine synthetase (Glul) and the switch from Gls2 to Gls1 glutaminase. In contrast to liver tumors, MYC-induced lung tumors display increased expression of both Glul and Gls1 and accumulate glutamine. We also show that inhibition of Gls1 kills cells that overexpress MYC and catabolize glutamine. Our results suggest that the metabolic profiles of tumors are likely to depend on both the genotype and tissue of origin and have implications regarding the design of therapies targeting tumor metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, inhibiting glutamine entry into the TCA cycle can blunt tumor progression in a MYC-driven cancer model of liver cancer (Xiang et al., 2015; Yuneva et al., 2012) and a MYC-inducible Burkitt lymphoma model (Le et al., 2012; Xiang et al., 2015).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2012
In the citing paper
“MYC has been found to increase mRNA and protein levels of glutamine transporters as well as expression of the enzyme glutaminase, which catalyzes the first step in glutaminolysis (Gao et al., 2009; Wise et al., 2008; Yuneva et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2012
In the citing paper
“Second, although different oncogenes reprogram metabolism in different ways, the tissue in which the oncogene is expressed affects the execution of metabolic reprogramming.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [5]
In the citing paper
“Transgenic MYC induces metabolic changes in both liver tumors and lung tumors but activates glutamine catabolism in lung tumors and glutamine synthesis in liver tumors.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [5]
In the citing paper
“MYC-driven cancer cells exhibit enhanced glutamine utilization accompanied by increased expression of key glutaminolysis enzymes, including GLS1/GLS2 and GLUD1178–180.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [179]
In the citing paper
“For example, liver tumors with aberrant overexpression of MYC display enhanced glutamine oxidation and sensitivity to therapies that target glutamine catabolism relative to liver tumors driven by overexpression of MET (196).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [196]
In the citing paper
“furthermore, a similar accumulation of glucose-derived glutamine within the tumor tissue was observed in a mouse model of c-Met-driven liver cancer (Yuneva et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Yuneva et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,346
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C., et al. (2009) · Cell · doi:10.1016/j.cell.2008.11.044 · Cited by 1,798
Wnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,456
Flagged first, then by citations
2 of the 64 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 638
Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2
Xiao, D., Ren, P., Su, H., Yue, M., Xiu, R., Hu, Y., Liu, H., & Qing, G. (2015) · Oncotarget · doi:10.18632/oncotarget.5821 · Cited by 80
miRNAs link metabolic reprogramming to oncogenesis
Hatziapostolou, M., Polytarchou, C., & Iliopoulos, D. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.03.002 · Cited by 84
Myc Expression Drives Aberrant Lipid Metabolism in Lung Cancer
Hall, Z., Ament, Z., Wilson, C. H., Burkhart, D. L., Ashmore, T., Koulman, A., Littlewood, T. D., Evan, G. I., & Griffin, J. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3403 · Cited by 83
Tumour Microenvironment Stress Promotes the Development of Drug Resistance
Seebacher, N. A., Krchniaková, M., Stacy, A. E., Skoda, J., & Jansson, P. J. (2021) · Antioxidants · doi:10.3390/antiox10111801 · Cited by 84
Androgen-regulated metabolism and biosynthesis in prostate cancer
Barfeld, S. J., Itkonen, H. M., Urbanucci, A., & Mills, I. G. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0515 · Cited by 78
Rodrigues, L. M., Uribe‐Lewis, S., Madhu, B., Honess, D. J., Stubbs, M., & Griffiths, J. R. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0166-z · Cited by 80
Hypoxia- and MicroRNA-Induced Metabolic Reprogramming of Tumor-Initiating Cells
Ullmann, P., Nurmik, M., Begaj, R., Haan, S., & Letellier, E. (2019) · Cells · doi:10.3390/cells8060528 · Cited by 77
Amoedo, N. D., Obre, E., & Rossignol, R. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.02.005 · Cited by 76
Exploiting tumor metabolism: challenges for clinical translation
Heiden, M. G. V. (2013) · Journal of Clinical Investigation · doi:10.1172/jci72391 · Cited by 79
Metabolic determinants of tumour initiation
Brunner, J. S., & Finley, L. W. S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00773-5 · Cited by 78
Identifying and targeting cancer-specific metabolism with network-based drug target prediction
Pacheco, M. P., Bintener, T., Ternes, D., Kulms, D., Haan, S., Letellier, E., & Sauter, T. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.046 · Cited by 77
Byun, J., Choi, Y., Kang, Y. N., Jang, B. K., Kang, K. J., Jeon, Y. H., Lee, H., Jeon, J., Koo, S., Jeong, W., et al. (2014) · Hepatology · doi:10.1002/hep.27577 · Cited by 75
Cancer Metabolism: A Modeling Perspective
Ghaffari, P., Mardinoğlu, A., & Nielsen, J. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00382 · Cited by 76
Metabolic rewiring in mutant Kras lung cancer
Kerr, E. M., & Martins, C. P. (2017) · FEBS Journal · doi:10.1111/febs.14125 · Cited by 76
Uo, T., Sprenger, C. C. T., & Plymate, S. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580617 · Cited by 76
Glutamine Synthetase: Localization Dictates Outcome
Castegna, A., & Menga, A. (2018) · Genes · doi:10.3390/genes9020108 · Cited by 75
Deregulated transcription factors in cancer cell metabolisms and reprogramming
Kant, R., Manne, R., Anas, M., Penugurti, V., Chen, T., Pan, B., Hsu, C.-C., & Lin, H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.10.001 · Cited by 76
Anderton, B. N., Camarda, R., Balakrishnan, S., Balakrishnan, A., Kohnz, R. A., Lim, L., Evason, K. J., Momčilović, O., Kruttwig, K., Huang, Q., et al. (2017) · EMBO Reports · doi:10.15252/embr.201643068 · Cited by 72
Nilsson, A., Haanstra, J. R., Engqvist, M. K. M., Gerding, A., Bakker, B. M., Klingmüller, U., Teusink, B., & Nielsen, J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919250117 · Cited by 71
Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer
Kreuzaler, P. A., Inglese, P., Ghanate, A. D., Gjelaj, E., Wu, V., Panina, Y., Méndez‐Lucas, A., Maclachlan, C., Patani, N., Hubert, C. B., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00915-7 · Cited by 71
Self-citationHeras, J. D. L., Aldamiz-Echevarria, L. J., Martínez‐Chantar, M. L., & Delgado, T. C. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1262843 · Cited by 70
Revisiting the Warburg Effect: Some Tumors Hold Their Breath
Sanderson, S. M., & Locasale, J. W. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.011 · Cited by 70
The MYC mRNA 3′‐UTR couples RNA polymerase II function to glutamine and ribonucleotide levels
Dejure, F. R., Royla, N., Herold, S., Kalb, J., Walz, S., Ade, C. P., Mastrobuoni, G., Vanselow, J. T., Schlösser, A., Wolf, E., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201796662 · Cited by 75
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68
GLS2 is protumorigenic in breast cancers
Dias, M. M., Adamóski, D., dos Reis, L. M., Ascenção, C. F. R., de Oliveira, K. R. S., Mafra, A. C. P., Bastos, A. C. D. S., Quintero, M., Cassago, C. A. D. G., Ferreira, I. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1007-z · Cited by 68
Li, X., Zhu, H., Sun, W., Yang, X., Nie, Q. H., & Fang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02121-5 · Cited by 69
Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization
Basnet, H., Tian, L. H., Ganesh, K., Huang, Y.-H., Macalinao, D. G., Brogi, E., Finley, L. W. S., & Massagué, J. (2019) · eLife · doi:10.7554/elife.43627 · Cited by 69
Savino, A. M., Fernandes, S. I., Olivares, O., Zemlyansky, A., Cousins, A., Markert, E. K., Barel, S., Geron, I., Frishman‐Levy, L., Birger, Y., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00115-2 · Cited by 70
Targeting fatty acid oxidation enhances response to HER2-targeted therapy
Nandi, I., Ji, L., Smith, H. W., Avizonis, D. Z., Papavasiliou, V., Lavoie, C. A., Pacis, A., Attalla, S. S., Sanguin‐Gendreau, V., & Muller, W. J. (2024) · Nature Communications · doi:10.1038/s41467-024-50998-3 · Cited by 68
Determinants of nutrient limitation in cancer
Sullivan, M. R., & Heiden, M. G. V. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1611733 · Cited by 70
Grinde, M. T., Hilmarsdóttir, B., Tunset, H. M., Henriksen, I. M., Kim, J., Haugen, M. H., Rye, M. B., Mælandsmo, G. M., & Moestue, S. A. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1141-0 · Cited by 65
A second Warburg‐like effect in cancer metabolism: The metabolic shift of glutamine‐derived nitrogen
Kodama, M., & Nakayama, K. I. (2020) · BioEssays · doi:10.1002/bies.202000169 · Cited by 65
The role of mitochondrial electron transport in tumorigenesis and metastasis
Tan, A. S., Baty, J. W., & Berridge, M. V. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.10.016 · Cited by 65
Targeting metabolism in breast cancer: How far we can go?
Long, J. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.122 · Cited by 65
Tran, T. Q., Gabra, M. B. I., Lowman, X. H., Yang, Y., Reid, M. A., Pan, M., O'Connor, T. R., & Kong, M. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2002810 · Cited by 65
Tsai, P.-Y., Lee, M.-S., Jadhav, U., Naqvi, I., Madha, S., Adler, A., Mistry, M., Naumenko, S., Lewis, C. A., Hitchcock, D. S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003014118 · Cited by 67
Rinaldi, G., Rossi, M., & Fendt, S. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1397 · Cited by 65
Icard, P., Simula, L., Fournel, L., Leroy, K., Mansuet‐Lupo, A., Damotte, D., Charpentier, M.-C., Durdux, C., Loi, M., Schussler, O., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100852 · Cited by 63
Mitochondrial uncoupling in cancer cells: Liabilities and opportunities
Baffy, G. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.01.005 · Cited by 64
Pachnis, P., Wu, Z., Faubert, B., Tasdogan, A., Gu, W., Shelton, S. D., Solmonson, A., Rao, A. D., Kaushik, A., Rogers, T. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn9550 · Cited by 65
Zhang, T., Watson, D. G., Wang, L., Abbas, M. N., Laura, M., Bashford, L., Ahmad, I., Lam, N.-Y., Ng, A. C. F., & Leung, H. Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065880 · Cited by 61
The combination of TRPM8 and TRPA1 expression causes an invasive phenotype in lung cancer
Du, G., Li, J., Liu, W.-J., Liu, Y.-H., Zhao, B., Li, H., Hou, X., Li, H., Qi, X., & Duan, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1167-3 · Cited by 60
The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis
Anderson, N. M., Li, D., Peng, H., Laroche, F., Mansour, M. R., Gjini, E., Aioub, M., Helman, D., Roderick, J. E., Cheng, T., et al. (2016) · Leukemia · doi:10.1038/leu.2016.26 · Cited by 60
De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
Tarrado‐Castellarnau, M., de Atauri, P., Tarragó‐Celada, J., Perarnau, J., Yuneva, M. O., Thomson, T. M., & Cascante, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167321 · Cited by 60
Self-citationRecent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase
Zimmermann, S. C., Duvall, B. R., & Tsukamoto, T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00327 · Cited by 59
Self-citationSevere metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance
Nwosu, Z. C., Piorońska, W., Battello, N., Zimmer, A. D., Dewidar, B., Han, M., Pereira, S., Blagojevic, B., Castven, D., Charlestin, V., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102699 · Cited by 61
Chen, Y., Li, Y., Huang, L., Du, Y., Gan, F., Li, Y., & Yao, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6620306 · Cited by 59
Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth
Zhao, J., Shi, S., Qu, H.-Y., Keckesova, Z., Cao, Z.-J., Yang, L., Yu, X., Feng, L., Shi, Z., Krakowiak, J., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-021-00524-2 · Cited by 58
Wang, X., Huang, Z., Li, Y.-L., Jin, K., Dong, D.-J., Wang, J., & Zhao, X. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010229 · Cited by 58
Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes
Sellers, K., Allen, T. D., Bousamra, M., Tan, J., Méndez‐Lucas, A., Lin, W., Bah, N. K., Chernyavskaya, Y., MacRae, J. I., Higashi, R. M., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0464-z · Cited by 57
Self-citationRegulation of hepatic glutamine metabolism by miR-122
Sengupta, D., Cassel, T., Teng, K., Aljuhani, M., Chowdhary, V., Hu, P., Zhang, X., Fan, T. W. ‐., & Ghoshal, K. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.003 · Cited by 57
Self-citationDual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC
Lee, J.-S., Kang, J. H., Lee, S.-H., Hong, D., Son, J., Hong, K. M., Song, J., & Kim, S.-Y. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.404 · Cited by 56
The requirement for pyruvate dehydrogenase in leukemogenesis depends on cell lineage
Jun, S., Mahesula, S., Mathews, T. P., Martin-Sandoval, M. S., Zhao, Z., Piskounova, E., & Agathocleous, M. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.016 · Cited by 58
Kaushik, A., Tarangelo, A., Boroughs, L. K., Ragavan, M., Zhang, Y., Wu, C., Li, X., Ahumada, K., Chiang, J., Tcheuyap, V. T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abp8293 · Cited by 56
In vivo Reprogramming of Cancer Metabolism by MYC
Camarda, R., Williams, J. R., & Goga, A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00035 · Cited by 56
Targeting Metabolic Changes in Cancer: Novel Therapeutic Approaches
Bobrovnikova-Marjon, E. V., & Hurov, J. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112344 · Cited by 56
13C Isotope-Assisted Methods for Quantifying Glutamine Metabolism in Cancer Cells
Zhang, J., Ahn, W. S., Gameiro, P. A., Keibler, M. A., Zhang, Z., & Stephanopoulos, G. N. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416618-9.00019-4 · Cited by 55
Kalfe, A., Telfah, A., Lambert, J., & Hergenröder, R. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b01603 · Cited by 57
Lane, A. N., Tan, J. D., Wang, Y., Yan, J., Higashi, R. M., & Fan, T. W. ‐. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.01.010 · Cited by 55
Self-citationThe Heterogeneity of Liver Cancer Metabolism
Salazar, J., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_9 · Cited by 57
Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells
Sun, Z., Zhang, Z., Wang, Q.-Q., & Liu, J.-L. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1707 · Cited by 58
Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
Läsche, M., Emons, G., & Gründker, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00409 · Cited by 55
Acidosis orchestrates adaptations of energy metabolism in tumors
Groessl, S., Kalis, R., Snaebjornsson, M. T., Wambach, L., Haider, J., Andersch, F., Schulze, A., Palm, W., & Zuber, J. A. (2025) · Science · doi:10.1126/science.adp7603 · Cited by 58
Birkenmeier, K., Dröse, S., Wittig, I., Winkelmann, R., Käfer, V., Döring, C., Hartmann, S., Wenz, T., Reichert, A. S., Brandt, U., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29934 · Cited by 56
Torrence, M. E., & Manning, B. D. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050329 · Cited by 55
Pan-cancer analysis of the metabolic reaction network
Gatto, F., Ferreira, R., & Nielsen, J. (2019) · Metabolic Engineering · doi:10.1016/j.ymben.2019.09.006 · Cited by 52
Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy
Nelson, B. S., Lin, L., Kremer, D. M., Sousa, C. M., Cotta‐Ramusino, C., Myers, A. L., Ramos, J., Gao, T., Kovalenko, I., Wilder-Romans, K., et al. (2020) · Cancer & Metabolism · doi:10.1186/s40170-019-0202-2 · Cited by 51
NMR-based Stable Isotope Resolved Metabolomics in systems biochemistry
Lane, A. N., & Fan, T. W. ‐. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.02.009 · Cited by 54
Self-citationMutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma
Crippa, S., Ancey, P., Vázquez, J., Angelino, P., Rougemont, A., Guettier, C., Zoete, V., Delorenzi, M., Michielin, O. A., & Meylan, E. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707814 · Cited by 53
Targeting Cell Metabolism as Cancer Therapy
Ngoi, N. Y. L., Eu, J. Q., Hirpara, J. L., Wang, L., Lim, J. S. J., Lee, S. C., Lim, Y., Pervaiz, S., Goh, B. C., & Wong, A. L. A. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7947 · Cited by 52
Parisi, F., Riccardo, S., Zola, S., Lora, C., Grifoni, D., Brown, L. M., & Bellosta, P. (2013) · Developmental Biology · doi:10.1016/j.ydbio.2013.04.008 · Cited by 50
Tumor Cells and Cancer-Associated Fibroblasts: An Updated Metabolic Perspective
Gentric, G., & Mechta‐Grigoriou, F. (2021) · Cancers · doi:10.3390/cancers13030399 · Cited by 52
Johnston, K., Pachnis, P., Tasdogan, A., Faubert, B., Zacharias, L. G., Vu, H., Rodgers-Augustyniak, L. A., Johnson, A., Huang, F., Ricciardo, S., et al. (2021) · Med · doi:10.1016/j.medj.2021.01.002 · Cited by 52
Sessions, D. T., Kim, K., Kashatus, J. A., Churchill, N., Park, K.-S., Mayo, M. W., Sesaki, H., & Kashatus, D. F. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111818 · Cited by 49
Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics
Pal, S., Sharma, A. K., Mathew, S. P., & Jaganathan, B. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955476 · Cited by 50
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Kumar, M. A., Baba, S. K., Khan, I. R., Khan, M. S., Husain, F. M., Ahmad, S., Haris, M., Singh, M., Akil, A. A., Macha, M. A., et al. (2025) · MedComm · doi:10.1002/mco2.70120 · Cited by 52
Stable Isotope-Labeled Tracers for Metabolic Pathway Elucidation by GC-MS and FT-MS
Higashi, R. M., Fan, T. W. ‐., Lorkiewicz, P. K., Moseley, H., & Lane, A. N. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1258-2_11 · Cited by 49
Self-citationSequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma
Dolezal, J. M., Wang, H., Kulkarni, S., Jackson, L. E., Lu, J. L., Ranganathan, S., Goetzman, E. S., Bharathi, S. S., Beezhold, K., Byersdorfer, C. A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.782052 · Cited by 50
NMR and MS-based Stable Isotope-Resolved Metabolomics and applications in cancer metabolism
Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2018) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2018.11.020 · Cited by 52
Self-citationGougèlet, A., Sartor, C., Senni, N., Caldéraro, J., Fartoux, L., Lequoy, M., Wendum, D., Talbot, J., Prignon, A., Chalaye, J., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.069 · Cited by 49
Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy
Gnocchi, D., Sabbà, C., Massimi, M., & Mazzocca, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043710 · Cited by 50
Glutamine at focus: versatile roles in cancer
Vitto, H. D., Pérez-Valencia, J. A., & Radosevich, J. A. (2015) · Tumor Biology · doi:10.1007/s13277-015-4671-9 · Cited by 54
Mammary epithelial cells have lineage-rooted metabolic identities
Mahendralingam, M. J., Kim, H., McCloskey, C. W., Aliar, K., Casey, A. E., Tharmapalan, P., Pellacani, D., Ignatchenko, V., García-Valero, M., Palomero, L., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00388-6 · Cited by 50
Yang, Z., Tian, T., Kong, J., & Chen, H. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06677 · Cited by 46
Cancer tissue of origin constrains the growth and metabolism of metastases
Sivanand, S., Gültekin, Y., Winter, P. S., Vermeulen, S. Y., Tchourine, K., Abbott, K. L., Danai, L. V., Gourgue, F., Do, B. T., Crowder, K. D., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01105-9 · Cited by 46
Drosophila Myc: A master regulator of cellular performance
Grifoni, D., & Bellosta, P. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.06.021 · Cited by 51
Li, S., Yin, Y., Clark, L. H., Sun, W., Sullivan, S. A., Tran, A.-Q., Han, J., Zhang, L., Guo, H., Madugu, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18854 · Cited by 46
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products
Chan, K. I., Zhang, S., Li, G., Xu, Y., Cui, L., Wang, Y., Su, H., Tan, W., & Zhong, Z. (2024) · Aging and Disease · doi:10.14336/ad.2023.0520 · Cited by 46
Hong, R., Zhang, W., Xia, X., Zhang, K., Wang, Y., Wu, M., Fan, J., Li, J., Xia, W., Xu, F., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12466 · Cited by 45
Lactic acid: The culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma
Peng, X., He, Z., Yuan, D., Liu, Z., & Rong, P. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189164 · Cited by 45
Action at a Distance: Allostery and the Development of Drugs to Target Cancer Cell Metabolism
DeLaBarre, B., Hurov, J., Cianchetta, G., Murray, S., & Dang, L. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.007 · Cited by 45
Werner, A., Pieh, D., Echchannaoui, H., Rupp, J., Rajalingam, K., Theobald, M., Closs, E. I., & Munder, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01268 · Cited by 44
Analyzing Tumor Metabolism In Vivo
Faubert, B., & DeBerardinis, R. J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121954 · Cited by 44
Colafati, G. S., Voicu, I. P., Carducci, C., Miele, E., Carai, A., Loreto, S. D., Marrazzo, A., Cacchione, A., Cecinati, V., Tornesello, A., et al. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418775375 · Cited by 43
Gautier, E. L., Westerterp, M., Bhagwat, N., Cremers, S., Shih, A. H., Abdel-Wahab, O. I., Lütjohann, D., Randolph, G. J., Levine, R. L., Tall, A. R., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121357 · Cited by 42
Lumata, L., Yang, C., Ragavan, M., Carpenter, N., DeBerardinis, R. J., & Merritt, M. E. (2015) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2015.04.006 · Cited by 42
Cetinbas, N. M., Sudderth, J., Harris, R. C., Cebeci, A., Negri, G. L., Yilmaz, Ö. H., DeBerardinis, R. J., & Sorensen, P. H. B. (2016) · Scientific Reports · doi:10.1038/srep32606 · Cited by 45
Metabolites and Immune Response in Tumor Microenvironments
Cortellino, S., & Longo, V. D. (2023) · Cancers · doi:10.3390/cancers15153898 · Cited by 43
Mapping cancer cell metabolism with 13 C flux analysis: Recent progress and future challenges
Young, J., Duckwall, C., & Murphy, T. A. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.115422 · Cited by 43
Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors
Patra, S., Elahi, N., Armorer, A., Arunachalam, S., Omala, J., Hamid, I., Ashton, A. W., Joyce, D. A., Jiao, X., & Pestell, R. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700629 · Cited by 43
Metadata
- Authors
- Yuneva, M. O., Fan, T. W. M., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., Matés, J. M., Alonso, F. J., Wang, C., Seo, Y., Chen, X., & Bishop, J. M.
- Affiliations
- University of California, San Francisco (US)
- University of Louisville (US)
- Johns Hopkins University (US)
- Universidad de Málaga (ES)
- Corresponding author
- Yuneva, Mariia O.
- ORCID
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 15
- Issue
- 2
- Pages
- 157-170
- ISSN
- 1550-4131 (ISSN-L)
- PMC
- PMC3282107
- OpenAlex
- W2036659083
- Cited by
- 639
- References
- 64
- Citations by year
- 2026: 17 · 2025: 37 · 2024: 35 · 2023: 41 · 2022: 53 · 2021: 66 · 2020: 43 · 2019: 59 · 2018: 45 · 2017: 63 · 2016: 47 · 2015: 39 · 2014: 42 · 2013: 34 · 2012: 16
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R35CA044338, R01CA118434)
- National Institute of Neurological Disorders and Stroke (R21NS074151)
- National Center for Research Resources (P20RR018733)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- cancer metabolism, c-Myc, MET, glutamine catabolism, glutamine synthetase, glutaminase, GLS1, GLS2, liver tumors, lung cancer, genetic lesions, glutamine accumulation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Citric Acid Cycle, Glucokinase, Glucose, Glutamine, Humans, Immunohistochemistry, Isotope Labeling, Liver Neoplasms, Experimental, Lung Neoplasms, Immunoblotting, Blotting, Western, Proto-Oncogene Proteins c-myc, DNA Primers, Lactic Acid, Proto-Oncogene Proteins c-met, Nuclear Magnetic Resonance, Biomolecular, RNA Interference, Cell Line, Tumor, Mice, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
